| Literature DB >> 27808480 |
Jialing Lin1, Ping Xu1, Yang Peng2, Dongxin Lin1, Qianting Ou1, Ting Zhang1, Chan Bai1, Xiaohua Ye1, Junli Zhou1, Zhenjiang Yao1.
Abstract
AIMS/Entities:
Keywords: zzm321990Staphylococcus aureuszzm321990; Diabetes; Methicillin-resistant Staphylococcus aureus
Mesh:
Year: 2016 PMID: 27808480 PMCID: PMC5415482 DOI: 10.1111/jdi.12591
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Prevalence of Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus nasal colonization
| Population |
|
| MRSA | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Adjusted | χ2 |
|
| Adjusted | χ2 |
| ||
| Diabetes | 529 | 46 (8.70%) | 8.09% | 2.77 | 0.096 | 22 (4.16%) | 3.70% | 1.25 | 0.263 |
| Non‐diabetes | 427 | 25 (5.85%) | 5.70% | 12 (2.81%) | 2.69% | ||||
Prevalence after adjusted for sex and age. MRSA, methicillin‐resistant Staphylococcus aureus; S. aureus, Staphylococcus aureus.
Influencing factors of Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus nasal colonization among the diabetic population
| Influencing factors |
|
| MRSA | ||||
|---|---|---|---|---|---|---|---|
|
| χ2 |
|
| χ2 |
| ||
| Demographic characteristics | |||||||
| Sex | |||||||
| Men | 161 | 8 (4.97) | 4.05 | 0.044 | 3 (1.86) | 3.06 | 0.080 |
| Women | 368 | 38 (10.33) | 19 (5.16) | ||||
| Age (years) | |||||||
| ≤65 | 267 | 25 (9.36) | 0.30 | 0.582 | 12 (4.49) | 0.15 | 0.696 |
| >65 | 262 | 21 (8.02) | 10 (3.82) | ||||
| BMI | |||||||
| <18.5 | 29 | 1 (3.45) | 1.72 | 0.632 | 1 (3.45) | 3.38 | 0.337 |
| 18.5–24.9 | 215 | 17 (7.91) | 11 (5.12) | ||||
| 25–27.9 | 210 | 20 (9.52) | 5 (2.38) | ||||
| ≥28 | 75 | 8 (10.67) | 5 (6.67) | ||||
| Monthly income (yuan) | |||||||
| <2000 | 469 | 40 (8.53) | – | 0.209 | 18 (3.84) | – | 0.197 |
| 2000–2999 | 43 | 6 (13.95) | 4 (9.30) | ||||
| ≥3000 | 17 | 0 (0.00) | 0 (0.00) | ||||
| Education | |||||||
| Illiterate | 91 | 11 (12.09) | 1.60 | 0.449 | 7 (7.69) | ||
| Primary school | 328 | 26 (7.93) | 11 (3.35) | – | 0.197 | ||
| Junior school and above | 110 | 9 (8.18) | 4 (3.64) | ||||
| Medical history | |||||||
| Type of diabetes | |||||||
| 1 | 19 | 0 (0.00) | – | 0.396 | 0 (0.00) | – | 1.000 |
| 2 | 507 | 46 (9.07) | 22 (4.34) | ||||
| Duration of diabetes (years) | |||||||
| <5 | 332 | 32 (9.64) | 3.40 | 0.183 | 17 (5.12) | – | 0.120 |
| 5–9 | 113 | 5 (4.42) | 1 (0.88) | ||||
| ≥10 | 84 | 9 (10.71) | 4 (4.76) | ||||
| Family history of diabetes | |||||||
| Yes | 109 | 12 (11.01) | 0.93 | 0.337 | 3 (2.75) | – | 0.591 |
| No | 420 | 34 (8.1) | 19 (4.52) | ||||
| Blood glucose monitoring | |||||||
| Yes | 271 | 26 (9.59) | 0.565 | 0.453 | 12 (4.43) | 0.10 | 0.751 |
| No | 258 | 20 (7.75) | 10 (3.88) | ||||
| Blood glucose controlling | |||||||
| Yes | 513 | 45 (8.77) | – | 1.000 | 22 (4.29) | – | 1.000 |
| No | 16 | 1 (6.25) | 0 (0.00) | ||||
| Well‐controlled blood glucose | |||||||
| Yes | 330 | 35 (10.61) | 4.03 | 0.045 | 18 (5.45) | 3.70 | 0.055 |
| No | 199 | 11 (5.53) | 4 (2.01) | ||||
| Taking insulin now | |||||||
| Yes | 186 | 16 (8.60) | 0.01 | 0.955 | 10 (5.38) | 1.07 | 0.302 |
| No | 343 | 30 (8.75) | 12 (3.50) | ||||
| Behavioral characteristics | |||||||
| Smoking | |||||||
| Yes | 77 | 3 (3.90) | 2.61 | 0.106 | 2 (2.60) | – | 0.756 |
| No | 452 | 43 (9.51) | 20 (4.42) | ||||
| Taking alcohol drinks | |||||||
| Yes | 26 | 0 (0.00) | – | 0.154 | 0 (0.00) | – | 0.617 |
| No | 503 | 46 (9.15) | 22 (4.37) | ||||
| Taking physical activity | |||||||
| Yes | 386 | 34 (8.81) | 0.02 | 0.880 | 19 (4.92) | 2.09 | 0.149 |
| No | 143 | 12 (8.39) | 3 (2.10) | ||||
| Antibiotic use past year | |||||||
| Yes | 121 | 8 (6.61) | 0.86 | 0.355 | 5 (4.13) | 0.00 | 0.987 |
| No | 408 | 38 (9.31) | 17 (4.17) | ||||
| Hospitalization past year | |||||||
| Yes | 244 | 23 (9.43) | 0.41 | 0.523 | 11 (4.51) | 0.11 | 0.742 |
| No | 280 | 22 (7.86) | 11 (3.93) | ||||
–, Calculated with Fisher's exact test; BMI, body mass index (weight [kg] / height [m]2); MRSA, methicillin‐resistant Staphylococcus aureus; S. aureus, Staphylococcus aureus.
Logistic regression analysis of influencing factors in Staphylococcus aureus nasal colonization among diabetic population
| Influencing factors | OR |
| 95% CI |
|---|---|---|---|
| Sex | |||
| Men | 0.45 | 0.047 | 0.20–0.99 |
| Women | 1.00 | ||
| Well‐controlled blood glucose | |||
| Yes | 2.04 | 0.047 | 1.01–4.13 |
| No | 1.00 | ||
CI, confidence interval; OR, odds ratio.
Antibiotic resistance of Staphylococcus aureus nasal colonization
| Antibiotic | Diabetic population | Non‐diabetic population |
|
| ||
|---|---|---|---|---|---|---|
| MRSA ( | MSSA ( | MRSA ( | MSSA ( | |||
| Cefoxitin | 10 (45.45) | 0 (0.00) | 6 (50.00) | 0 (0.00) | 0.828 | 0.800 |
| Linezolid | 1 (4.55) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1.000 | 1.000 |
| Penicillin | 21 (95.45) | 20 (83.33) | 12 (100.00) | 12 (92.31) | 0.320 | 0.453 |
| Gentamycin | 6 (27.27) | 3 (12.50) | 2 (16.67) | 1 (7.69) | 0.417 | 0.486 |
| Teicoplanin | 13 (59.09) | 17 (70.83) | 4 (33.33) | 5 (38.46) | 0.018 | 0.151 |
| Erythromycin | 18 (81.82) | 16 (66.67) | 9 (75.00) | 3 (23.08) | 0.029 | 0.638 |
| Trimethoprim‐sulfamethoxazol | 5 (22.73) | 1 (4.17) | 3 (25.00) | 0 (0.00) | 0.900 | 0.881 |
| Tobramycin | 7 (31.82) | 5 (20.83) | 3 (25.00) | 5 (38.46) | 0.597 | 0.677 |
| Moxifloxacin | 8 (36.36) | 3 (12.50) | 4 (33.33) | 0 (0.00) | 0.435 | 0.860 |
| Rifampicin | 3 (13.64) | 2 (8.33) | 2 (16.67) | 4 (30.77) | 0.144 | 0.812 |
| Clindamycin | 13 (59.09) | 7 (29.17) | 8 (66.67) | 7 (53.85) | 0.184 | 0.664 |
Data presented as n (%). *P‐value was calculated the antibiotic resistance proportions of Staphylococcus aureus between the two populations.
**P‐value was calculated the antibiotic resistance proportions of methicillin‐resistant Staphylococcus aureus (MRSA) between the two populations.
***P‐value was calculated with Fisher's exact test. MSSA, methicillin‐sensitive Staphylococcus aureus.
Genotypic and phenotypic characteristics of methicillin‐resistant Staphylococcus aureus nasal colonization
| Population | CC | MLST | SCC | PVL | MDR | Antibiotic resistance patterns |
|---|---|---|---|---|---|---|
| Diabetes ( | CC5 | ST544 | IV | – | + | PEN‐GEN‐TEC‐TOB |
| CC5 | ST1 | NT | – | + | PEN‐TEC‐ERY‐SXT‐TOB‐MXF‐CLI | |
| CC5 | ST1 | II | – | + | FOX‐PEN‐GEN‐ERY‐TOB‐MXF‐CLI | |
| CC5 | ST6 | NT | + | – | – | |
| CC5 | ST6 | I | – | – | PEN‐TEC‐CLI | |
| CC5 | ST5 | V | – | + | PEN‐GEN‐ERY‐SXT‐CLI | |
| CC5 | ST72 | IV | – | – | FOX‐PEN‐ERY | |
| CC5 | ST9 | IV | – | + | FOX‐PEN‐GEN‐ERY‐SXT‐TOB‐CLI | |
| CC5 | ST188 | NT | – | – | PEN‐TEC | |
| CC30 | ST30 | IV | – | – | PEN‐TEC‐ERY | |
| CC45 | ST45 | IV | – | + | FOX‐PEN‐TEC‐ERY‐CLI | |
| CC45 | ST3154 | NT | – | – | FOX‐PEN‐TEC‐ERY | |
| CC59 | ST338 | III | + | + | FOX‐PEN‐TEC‐ERY‐MXF‐CLI | |
| CC59 | ST338 | III | + | + | FOX‐PEN‐ERY‐SXT‐CLI | |
| CC59 | ST59 | IV | – | + | LZD‐FOX‐PEN‐ERY‐MXF‐CLI | |
| CC59 | ST59 | V | – | + | FOX‐PEN‐TEC‐ERY‐MXF‐CLI | |
| CC182 | ST944 | II | – | – | PEN‐ERY‐CLI | |
| CC398 | ST398 | V | – | + | PEN‐GEN‐ERY‐SXT‐TOB‐MXF‐CLI | |
| CC398 | ST2504 | V | – | + | PEN‐GEN‐TEC‐ERY‐TOB‐MXF‐CLI | |
| CC398 | ST1937 | II | – | + | FOX‐PEN‐TEC‐ERY‐MXF‐CLI | |
| CC398 | ST398 | III | – | + | PEN‐TEC‐ERY‐CLI | |
| CC398 | ST398 | NT | – | + | PEN‐TEC‐ERY‐TOB | |
| Non‐diabetes ( | CC5 | ST9 | IV | – | + | FOX‐PEN‐GEN‐TEC‐ERY‐SXT‐TOB‐MXF‐RIF‐CLI |
| CC5 | ST544 | IV | – | – | PEN | |
| CC5 | ST544 | IV | + | – | PEN‐TEC | |
| CC5 | ST72 | II | – | + | PEN‐TEC‐ERY‐MXF‐CLI | |
| CC5 | ST5 | V | – | + | FOX‐PEN‐ERY‐MXF‐CLI | |
| CC7 | ST7 | IV | – | + | PEN‐GEN‐ERY‐SXT‐TOB‐CLI | |
| CC30 | ST30 | IV | – | – | PEN‐ERY‐MXF | |
| CC59 | ST59 | IV | – | – | FOX‐PEN‐ERY‐CLI | |
| CC59 | ST59 | IV | – | – | FOX‐PEN‐ERY‐CLI | |
| CC59 | ST338 | III | + | – | FOX‐PEN‐ERY‐CLI | |
| CC88 | ST88 | NT | + | + | FOX‐PEN‐ERY‐SXT‐TOB‐RIF‐CLI | |
| CC2483 | ST2483 | III | – | – | PEN‐TEC |
+, Positive; –, negative; CC, clonal complex; CLI, clindamycin; ERY, erythromycin; FOX, cefoxitin; GEN, gentamycin; LZD, linezolid; MDR, multidrug resistant; MLST, multilocus sequence typing; MXF, moxifloxacin; NT, non‐typeable; PEN, penicillin; PVL, Panton–Valentine leukocidin; RIF, rifampicin; SCC, staphylococcal chromosome cassette; ST, sequence type; SXT, trimethoprim‐sulfamethoxazol; TEC, teicoplanin; TOB, tobramycin.